In the late 1980s, it was concluded that there was no evidence confirming the effectiveness of glaucoma treatment. For the most part, this finding was considered baseless by practitioners. And in response, the glaucoma community launched several benchmark randomized trials evaluating the benefit of intraocular pressure reduction. The randomized clinical trial is now considered the most reliable form of scientific evaluation for intervention effectiveness.
This module reviews the design and results of major multicenter, randomized, and clinical glaucoma trials. Also examined is the clinical application of study results.
Upon completion of this module, the reader should be able to:
- Describe the study designs of multicenter randomized clinical trials in glaucoma.
- Discuss the major findings of clinical trials in glaucoma.
- Apply results of glaucoma clinical trials to patient care.
Authors: Steven J. Gedde, MD, Kateki Vinod, MD
Consultants: Daniel Lee, MD, Carla J. Siegfried, MD
Focal Points issues are practical, hands-on discussions of the clinical issues you face daily. Each issue delivers high-quality, trusted ophthalmic information written and reviewed by leading experts.
Subscribers receive 12 issues a year, plus access to the Focal Points digital archive.
To access this issue from your laptop or desktop computer, log in to www.aao.org/myonlineproducts with your Academy username and password.
To access this issue from your smartphone or tablet, use the free AAO eBooks app.
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.